Vanda Pharmaceuticals Inc

詳細情報 Vanda Pharmaceuticals Inc 企業名

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Vanda Pharmaceuticals Incの企業情報



企業コードVNDA

会社名Vanda Pharmaceuticals Inc

上場日Apr 12, 2006

最高経営責任者「CEO」Dr. Mihael Hristos Polymeropoulos, M.D.

従業員数368

証券種類Ordinary Share

決算期末Apr 12

本社所在地Suite 300E

都市WASHINGTON

証券取引所NASDAQ Global Market Consolidated

国United States of America

郵便番号20037

電話番号12027343400

ウェブサイトhttps://www.vandapharma.com/

企業コードVNDA

上場日Apr 12, 2006

最高経営責任者「CEO」Dr. Mihael Hristos Polymeropoulos, M.D.

Vanda Pharmaceuticals Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.34M

+0.43%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

Dr. Stephen Ray Mitchell, M.D.

Independent Director

97.08K

+116.43%

Mr. Timothy I. Williams

Senior Vice President, General Counsel, Secretary

--

Ms. Phaedra S. Chrousos

Independent Director

--

Mr. Joakim (Kim) Wijkstrom

Senior Vice President, Chief Marketing Officer

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.34M

+0.43%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Fanapt

29.29M

55.70%

Hetlioz

16.19M

30.79%

PONVORY

7.10M

13.51%

データなし

事業別

地域別

事業別USD

会社名

収益

比率

Fanapt

29.29M

55.70%

Hetlioz

16.19M

30.79%

PONVORY

7.10M

13.51%

株主

更新時刻: Fri, Aug 15

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

10.13%

The Vanguard Group, Inc.

5.99%

Renaissance Technologies LLC

5.83%

Millennium Management LLC

5.28%

Dimensional Fund Advisors, L.P.

4.38%

他の

68.39%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

10.13%

The Vanguard Group, Inc.

5.99%

Renaissance Technologies LLC

5.83%

Millennium Management LLC

5.28%

Dimensional Fund Advisors, L.P.

4.38%

他の

68.39%

種類

株主統計

比率

Investment Advisor

27.57%

Investment Advisor/Hedge Fund

27.14%

Hedge Fund

19.34%

Individual Investor

7.19%

Research Firm

3.40%

Pension Fund

0.72%

Bank and Trust

0.20%

Sovereign Wealth Fund

0.19%

Venture Capital

0.05%

他の

14.18%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

373

46.47M

78.64%

-9.95M

2025Q2

417

50.75M

85.90%

-11.31M

2025Q1

426

48.51M

82.37%

-12.27M

2024Q4

444

46.48M

79.71%

-15.23M

2024Q3

446

47.42M

81.36%

-14.93M

2024Q2

445

46.99M

80.73%

-18.42M

2024Q1

434

53.50M

92.97%

-11.41M

2023Q4

445

55.38M

96.27%

-9.21M

2023Q3

446

56.79M

98.75%

-12.15M

2023Q2

434

60.42M

105.19%

-10.16M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

5.99M

10.13%

-31.47K

-0.52%

Jun 30, 2025

The Vanguard Group, Inc.

3.54M

5.99%

+46.84K

+1.34%

Jun 30, 2025

Renaissance Technologies LLC

3.45M

5.83%

-118.97K

-3.34%

Jun 30, 2025

Millennium Management LLC

3.12M

5.28%

+980.75K

+45.84%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

2.59M

4.38%

+46.08K

+1.81%

Jun 30, 2025

BlackRock Financial Management, Inc.

2.43M

4.12%

+286.64K

+13.35%

Jun 30, 2025

Tang Capital Management, LLC

2.35M

3.98%

--

Jun 30, 2025

Polymeropoulos (Mihael Hristos)

2.34M

3.95%

+10.00K

+0.43%

Aug 07, 2025

Acadian Asset Management LLC

1.73M

2.93%

-155.16K

-8.22%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.69M

2.86%

+78.00K

+4.83%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

詳細情報 Vanda Pharmaceuticals Inc 企業名

Vanda Pharmaceuticals Incの企業情報

Vanda Pharmaceuticals Incの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割